Zai Lab's Q1 revenues rise 22%, pipeline advances

Zai Lab (HKEX: 9688) announced its Q1 2025 results, showcasing a 22% year-over-year revenue increase to $106.5 million, driven primarily by strong sales of VYVGART, ZEJULA, and NUZYRA. The company reaffirms its full-year 2025 revenue guidance between $560 million and $590 million. Operating loss improved by 20% to $56.3 million, or 25% to $37.1 million on an adjusted basis, with Zai Lab on track to achieve profitability in Q4 2025.